VANDELLI, Carmen
 Distribuzione geografica
Continente #
NA - Nord America 2.131
EU - Europa 890
AS - Asia 329
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
SA - Sud America 1
Totale 3.354
Nazione #
US - Stati Uniti d'America 2.123
GB - Regno Unito 300
SE - Svezia 206
CN - Cina 120
IT - Italia 111
DE - Germania 93
TR - Turchia 75
HK - Hong Kong 70
UA - Ucraina 57
SG - Singapore 50
FI - Finlandia 44
BG - Bulgaria 26
NL - Olanda 13
BE - Belgio 12
FR - Francia 10
CA - Canada 7
CZ - Repubblica Ceca 7
IE - Irlanda 6
IN - India 4
EU - Europa 2
ID - Indonesia 2
IR - Iran 2
KR - Corea 2
MY - Malesia 2
PL - Polonia 2
AU - Australia 1
BZ - Belize 1
CL - Cile 1
IL - Israele 1
LT - Lituania 1
PT - Portogallo 1
RO - Romania 1
VN - Vietnam 1
Totale 3.354
Città #
Fairfield 284
Southend 229
Woodbridge 222
Ashburn 202
Chandler 198
Houston 175
Ann Arbor 127
Wilmington 122
Jacksonville 119
Nyköping 97
Dearborn 89
Seattle 84
Cambridge 78
Hong Kong 70
Izmir 50
Singapore 33
Beijing 32
Princeton 30
San Diego 30
Sofia 26
Des Moines 25
Eugene 25
Boardman 19
Modena 17
Shanghai 17
Helsinki 16
Amsterdam 11
Brussels 11
London 11
Los Angeles 10
New York 9
Reggio Nell'emilia 9
Falls Church 8
Dublin 6
Frankfurt am Main 6
Redwood City 6
San Mateo 6
Bologna 5
Bremen 5
Hefei 5
Auburn Hills 4
Brno 4
Kunming 4
Milan 4
Munich 4
Norwalk 4
Turku 4
Grafing 3
Guangzhou 3
Kilburn 3
Olomouc 3
Ottawa 3
Toronto 3
Augusta 2
Busto Arsizio 2
Dallas 2
Gimpo-si 2
Groningen 2
Leawood 2
Nanchang 2
Parma 2
Philadelphia 2
Prescot 2
Tulare 2
Verona 2
Wuhan 2
Adelaide 1
Ankara 1
Argelato 1
Belize City 1
Belpasso 1
Calcinaia 1
Cantalice 1
Casapulla 1
Cassano Magnago 1
Changchun 1
Chicago 1
Chiswick 1
Cilacap 1
Citta 1
Dongguan 1
Dung 1
Faenza 1
Falkenstein 1
Fuzhou 1
Gandhi Nagar 1
Hounslow 1
Jakarta 1
Jining 1
Lanzhou 1
Leiria 1
Mariano Comense 1
Marseille 1
Mezzocorona 1
Monmouth Junction 1
Montreal 1
Nanjing 1
Polesella 1
Pune 1
Rimini 1
Totale 2.630
Nome #
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 210
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases 206
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 171
Fibrosis progression in HCV carriers with mild hepatitis who possess the high-repetition variant of the DRD4 gene, a genetic marker for binge-drinking and risk-seeking behavior: a longitudinal study 166
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 159
Chronic hepatitis C and psychosocial distress 157
Parametri predittivi e risposta sostenuta alla terapia antivirale combinata nell'epatite cronica attivva HCV correlata (ECA HCV) 153
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve mono-infected HCV patients. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milano,Italia, 23-27 Aprile, 2008. 147
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy 147
Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study 143
The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases 140
A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon 121
Analysis of factors involved in fibrosis progression among hepatitis C virus carriers with normal alanine aminotransferares. 41st Annual Meeting of the European Association for the Study of the Liver (EASL).Vienna, Austria, 26-30 Aprile 2006. 120
The virologic and histologic status in anti HCV+ve subjects with normal ALT levels: results of a ten year prospective follow-up study. 120
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve mono-infected HCV patients. 117
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 117
Genetic polymorphisms of interleukin-6 modulates fibrosis progression in mild chronic hepatitis C. 107
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients. 107
Demographic, etiological and clinical features of 500 consecutive patients with liver cirrhosis at the onset of the first episode of decompensation. 50th Anniversary Meeting of the International Association for the Study of Liver Diseases (AASLD). San Francisco, 31 Ottobre- 4 Novembre 2008. 105
Long-term interferon therapy in patients with refractory chronic hepatitis C: effect on histological liver damage and hepatocellular carcinogenesis. 103
Demographic, etiological and clinical features of 500 consecutive patients with liver cirrhosis at the onset of the first episode of decompensation. 50th Anniversary Meeting of the International Association for the Study of Liver Diseases (AASLD) 100
Metodologia per l’adozione di linee guida cliniche in Medicina Interna. 98
Prediciting the natural history of patients with epatitis C and persistently normal transaminases: a longitudinal long term study with dual biopsies. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). 98
Health-related quality of life in recent and long standing chronic HCV infection. 95
Hepatitis C virus carriers with normal alanine aminotransferases: analysis of factors involved in fibrosis progression. 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). Barcellona, Spagna, 11-15 aprile 2007. 93
Prediciting the natural history of patients with epatitis C and persistently normal transaminases: a longitudinal long term study with dual biopsies. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milano, Italia, 23-27 Aprile, 2008. 79
Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C 2
Totale 3.381
Categoria #
all - tutte 14.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020484 0 0 0 43 48 105 99 53 50 21 39 26
2020/2021565 47 11 44 69 38 43 90 67 21 57 43 35
2021/2022476 9 58 50 59 13 24 26 13 56 34 90 44
2022/2023526 61 68 36 46 63 92 3 52 84 2 11 8
2023/2024318 8 21 14 32 49 19 52 79 6 2 11 25
2024/2025107 36 13 7 51 0 0 0 0 0 0 0 0
Totale 3.381